Work

Therapeutics Letter 93

Year: 2015

Type: article

Abstract: Therapeutics Letter 93 considers whether claims for newer drugs for overactive bladder are warranted. Conclusions: All drugs for overactive bladder have limited short-term potential benefit and appreciable risk of adverse effects. There is insufficient evidence that benefits of long-term treatment outweigh harm for any overactive bladder drug. Claims of superiority for any antimuscarinic drug (including fesoterodine and oxybutynin chloride gel) over the others are not warranted due to methodological shortcomings of available RCTs. Mirabegron is a poor alternative due to its lack of an efficacy advantage and cardiac risks. Recent observational studies suggest that all longterm anticholinergic drugs increase risk of dementia.

Source: cIRcle (University of British Columbia)

Author: Therapeutics Initiative (University of British Columbia)

Language: English

Topic: Urinary Bladder and Prostate Research

Subfield: Urology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7210702752

FWCI:

Cites: 6

Cited by:

Related to: 10